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Defining the Role of Hemithorax Irradiation
for Thymomas Is Difficult
Steven E. Schild, MD
Sugie et al. evaluated postoperative mediastinal radiotherapy(MRT) for invasive thy-moma with low-dose entire hemithorax radiotherapy (EHRT) for pleural dissemina-
tion.1 This was done to clarify the role of EHRT.
Following removal of disseminated lesions, EHRT was given to 12 patients with
pleural dissemination using doses of 11.2 to 16 Gy in 7 to 10 fractions (mean dose: 14.1
Gy). This was given in addition to MRT which included 30 to 64 Gy (mean: 44 Gy)
depending on the extent of the disease. They treated 52 patients with MRT alone and eight
with EHRT  MRT. Of these eight patients, seven had stage IVa disease and one had
stage II disease with tumor spillage at the time of resection. They also gave EHRT to
another four of these patients who later developed pleural dissemination. Twenty-four of
the 60 (40%) patients also received chemotherapy.
Survival was associated with the Masaoka stage (p  0.048) and extent of resection
(p  0.0046), but not the extent of radiotherapy (RT). The pleural control rate for stage
IVa patients was relatively high (71% at 3 years) in patients undergoing EHRT  MRT
compared with 49% in those receiving MRT alone, although this difference was not
significant (p  0.38). Overall survival and local control rates did not differ significantly
based on extent of RT. Severe (grade 3) RT related toxicity occurred in 1 (2%) of the 52
patients who received MRT compared with 1 (8.3%) of the 12 patients who received
EHRT  MRT.
The authors conclude that new radiation techniques like intensity modulated
radiotherapy (IMRT) would improve the outcome by increasing the dose and reducing the
possibility of radiation pneumonitis. IMRT has been used widely in the United States
since the year 2000. The basic concept is to tightly conform the RT to a target by the
converting a single radiation field of a uniform intensity to a field composed of many tiny
subfields, each with its own intensity. Thus, the intensity of radiation varies across the
field. Many radiation beams (often 7) all coming from different angles of attack are
added together to deliver the dose. IMRT allows one to create dose plans that tightly wrap
radiation around targets. IMRT has allowed radiation oncologists to administer greater
doses of RT more safely than three-dimensional RT. IMRT is dependent on a high level
of computer technology only recently available. However, even if one could administer a
greater dose more safely to the periphery of the thoracic cavity with IMRT, it may not
completely address thymoma cells floating in the pleural fluid. To spare lung from
radiation using IMRT, one would need to spare the pleural space within the lung fissures.
It is quite possible these portions of the pleural space would act as a sanctuary for
thymoma cells disseminated in the pleural space. However, despite this concern, more
research is warranted using IMRT to see whether it can be more successfully used for
thymomas than other RT systems. Sugie et al. recommended EHRT  MRT for patients
with nonextensive pleural dissemination and good postoperative pulmonary function
using a multidisciplinary approach. Based on their data, one can question the value of this
approach because EHRT was not shown to significantly improve survival nor decrease
toxicity.
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However, this is not the entire story of EHRT use for
thymomas. M. Uematsu et al. evaluated prophylactic EHRT in
addition to MRT following a complete resection of stages II and
III invasive thymoma. Forty-three patients had a complete sur-
gical resection and then received EHRTMRT or MRT alone.
In most cases, EHRT was 15 Gy/15 fractions over 3 weeks
(without inhomogeneity corrections). In both the EHRTMRT
and MRT group, the total radiation doses to the mediastinum
were similar with a median of 40 Gy. Only one of the 23(4%)
patients with EHRTMRT relapsed compared with eight of the
20(40%) with MRT. The pleura was the most common site of
failure. At 5 years, the relapse-free rate was 100% for those
receiving EHRTMRT compared with 66% with MRT (p 
0.03). The overall survival rate was 96% for those with EHRT 
MRT compared with 74% for those with MRT (p  not
significant). The only significant treatment-related complication
was radiation pneumonitis requiring treatment in one (5%) of the
20 patients who received MRT and three (13%) of 23 who
received EHRTMRT. They concluded that except for elderly
patients (who they felt were predisposed to toxicity), “EHRT
MRT following a macroscopically complete resection appeared
to be safe and feasible, and reduced intrathoracic relapses.”2
Yoshida et al. evaluated 11 thymoma patients with
thoracic dissemination and less than complete resection. RT
was administered postoperatively in all patients. RT doses
ranged from 10 to 17 Gy to the entire hemithorax of the
disseminated site and from 30 to 55 Gy to the primary tumor
bed. Chemotherapy of various types was administered prior
to RT in 7 cases. The 5- and 10-year survival rates were 80
and 64%, respectively. Six of the 11 patients were free from
recurrence with a median follow-up of 60 months. EHRT was
suggested as postoperative or definitive treatment for most
patients with pleural spread of thymoma.3
Thus, it is difficult with the available data to be show
that EHRT  MRT significantly improve the survival of
patients who have had complete resection compared with
MRT alone based on the studies of Sugie et al. and Uematsu
et al.1,2 However, for patients who have had less than a
complete resection, EHRT  RT appear to salvage a large
fraction of patients with pleural dissemination.3 Based on the
large French Experience of Cowen et al., four factors were
associated with poorer survival: mediastinal compression on
presentation (p  0.001), absence of chemotherapy (p 
0.001), biopsy alone (p 0.003), and young age (p 0.013).
Thus, an overall treatment plan should integrate resection
(which should be as complete as possible) with RT for given
invasive thymomas going beyond the capsule,4 and chemo-
therapy used for those with advanced disease (stage III-IVa
disease and mediastinal compression on presentation). Che-
motherapy and/or RT can also be used preoperatively to
potentially improve resectability.5,6
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